Clinical Trials Logo

Metastatic Carcinoma clinical trials

View clinical trials related to Metastatic Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04939246 Active, not recruiting - Clinical trials for Metastatic Carcinoma

Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

SMART ONE
Start date: June 18, 2021
Phase: N/A
Study type: Interventional

This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.

NCT ID: NCT04376502 Active, not recruiting - Clinical trials for Metastatic Carcinoma

Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.

Start date: April 8, 2020
Phase: N/A
Study type: Interventional

This is an open label single arm phase 2 clinical trial in patients with metastatic solid malignancy of any histology who have previously experienced limited progression in at least 1 and up to 5 lesions while on immune checkpoint inhibitors monotherapy.

NCT ID: NCT02960282 Terminated - Clinical trials for Stage IV Colorectal Cancer

Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy

Start date: October 20, 2016
Phase:
Study type: Observational

This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy. Studying samples of feces from patients with metastatic cancer in the laboratory may help doctors learn if the make-up of the gut microbiome has a positive or negative influence to a patient's response to chemotherapy or immunotherapy.

NCT ID: NCT02730923 Active, not recruiting - Clinical trials for Endometrial Carcinoma

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

VICTORIA
Start date: April 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators hypothesize that the dual inhibition of mTORC1/mTORC2 by AZD2014 combined with inhibition of aromatase enzyme by anastrozole will act synergistically and may be an interesting therapeutic option for endometrial cancer with a manageable toxicity profile. The investigators proposal is to conduct a multicenter, 2-step, randomized, Phase I/II trial to evaluate the safety and efficacy of a combination treatment associating anastrozole to AZD2014 in advanced endometrial cancer patients. The study is divided in 2 steps : - A safety run-in phase aiming to evaluate the safety of the proposed combination AZD2014 + anastrozole (Arm A) versus anastrozole alone (Arm B). No dose escalation is scheduled (doses are based on maximum tolerated dose (MTD) defined for AZD2014 and the summary of product characteristics (SPC) of anastrozole). However, dose de-escalation for AZD2014 will be applied in case of toxicity. - A two-stage randomized Phase II part aiming to evaluate the clinical benefit of the AZD2014 + anastrozole (Arm A) combination therapy versus anastrozole (Arm B).

NCT ID: NCT02605811 Recruiting - Clinical trials for Small Cell Lung Cancer

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Start date: September 2015
Phase: Phase 2
Study type: Interventional

To investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

NCT ID: NCT02192346 Completed - Metastatic Sarcoma Clinical Trials

α-TEA in Advanced Cancer

Start date: August 4, 2014
Phase: Phase 1
Study type: Interventional

The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.

NCT ID: NCT01469598 Completed - Clinical trials for Metastatic Carcinoma

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Start date: August 2011
Phase: Phase 2
Study type: Interventional

Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of DNA synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and inhibits microtubule depolymerization. In this study, patients received gemcitabine 900 mg/m2 on days 1 and 8 plus docetaxel 100 mg/m2 on day 8 with G-CSF support every 3 week.

NCT ID: NCT01320241 Completed - Pancreatic Cancer Clinical Trials

Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture

Start date: November 2008
Phase: Phase 2
Study type: Interventional

Malignant biliary obstruction is a common clinical condition caused by various malignancies. Currently,biliary stent implantation guided either by fluoroscopy or endoscopy has become the most important methods for relieving malignant biliary obstruction. However, the benefit for the survival of the patients with palliation of the stent treatment is limited because no therapeutic effects on process of the tumor itself by a stent implantation. Encouraged by the success of 125I esophageal stent in esophageal carcinoma, a novel biliary stent loaded with 125I radioactive seeds has been developed in our institute. After ex vivo and in vivo evaluations for the delivery system, the investigators prospectively compare the responses to treatment with this radiation biliary stent, versus the conventional biliary SEMS in patient with malignant biliary obstruction.